Bile Duct Diseases
24 drugs in active Bile Duct Diseases trials · Updated 18 Nov 2026
Furthest along
1 approved
8 in Phase 3
Drugs
24
In active trials, any stage
Trials
38 active
5 sub-diseases included
Drugs24
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Peroxisome proliferator-activated receptor agonist |
Phase 3 | 17 Dec 2026soonPhase 3 trial completes | |||
| Next date | 17 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis and 2 more | ||||
| Open drug page | |||||
— |
Phase 3 | 31 Dec 2026Phase 2 trial completes | |||
| Next date | 31 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Chronic Cholecystitis, Biliary Dyskinesia | ||||
| Open drug page | |||||
Ileal bile acid transporter inhibitor |
Phase 3 | 15 Feb 2027Phase 3 trial completes | |||
| Next date | 15 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Alagille Syndrome, Biliary Atresia | ||||
| Open drug page | |||||
— |
Phase 3 | 18 Apr 2027Phase 3 trial completes | |||
| Next date | 18 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Primary Biliary Cholangitis, Cholestatic Liver Disease | ||||
| Open drug page | |||||
— |
Phase 3 | Sep 2027Phase 3 trial completes | |||
| Next date | Sep 2027 · Phase 3 trial completes | ||||
| Also tested for | Primary Sclerosing Cholangitis | ||||
| Open drug page | |||||
Ileal bile acid transporter inhibitor |
Phase 3 | 23 Oct 2028Phase 3 trial completes | |||
| Next date | 23 Oct 2028 · Phase 3 trial completes | ||||
| Also tested for | Pruritus | ||||
| Open drug page | |||||
— |
Gilead (Kite) · Public GILD |
Phase 3 | Nov 2028Phase 3 trial completes | ||
| Next date | Nov 2028 · Phase 3 trial completes | ||||
| Also tested for | Primary Biliary Cholangitis, Primary Biliary Cirrhosis | ||||
| Open drug page | |||||
PD-1/TIGIT bispecific antibody |
AstraZeneca · Public AZN |
Phase 3 | 2 Jan 2029Phase 3 trial completes | ||
| Next date | 2 Jan 2029 · Phase 3 trial completes | ||||
| Also tested for | Biliary Tract Cancer | ||||
| Open drug page | |||||
— |
Phase 2 | 31 Dec 2026Phase 2 trial completes | |||
| Next date | 31 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | Jan 2027Phase 2 trial completes | |||
| Next date | Jan 2027 · Phase 2 trial completes | ||||
| Also tested for | Primary Sclerosing Cholangitis, Primary Biliary Cholangitis and 1 more | ||||
| Open drug page | |||||
No drugs match “”.
Included5
| Sub-disease | Drugs | Active trialsTrials |
|---|---|---|
| Cholestasis 3 sub-diseases | 10 | 18 |
| Cholangitis 1 sub-disease | 7 | 9 |
| Bile Duct Neoplasms | 9 | 9 |
| Common Bile Duct Diseases 1 sub-disease | 2 | 4 |
| Biliary Atresia | 2 | 2 |
How trials write it1
The conditions trials list that we place on Bile Duct Diseases itself, with their active trials
Cholestatic Liver Disease 2
About
- Summary
- 24 drugs are in active Bile Duct Diseases trials: 1 approved, 8 in Phase 3, 15 earlier. The next Phase 3 result expected is Elafibranor’s, 17 Dec 2026. Updated 18 Nov 2026.
- Registry term
- Bile Duct Diseases
- Counts
- Active trials the registry tags with the term or a term under it, at any stage. A search also reads trial titles and drug names, so its counts differ.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026